Regeneron Pharmaceuticals Inc Revenue Growth Rates (REGN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Regeneron Pharmaceuticals Inc   (NASDAQ: REGN)
 

REGN's Revenue Growth by Quarter and Year

Regeneron Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

REGN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 4,290.70
1st Quarter March 3,605.40
FY 7,896.10

REGNs Annual Revenue
Regeneron Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 14,342.90 millions
Regeneron Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 14,202.00 millions
Regeneron Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 13,117.20 millions
Regeneron Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 12,172.90 millions
Regeneron Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 16,071.70 millions




REGN Revenue second quarter 2026 Y/Y Growth Comment
Regeneron Pharmaceuticals Inc reported Revenue increase of 16.73% year on year in the second quarter 2026, to $ 4,290.70 millions, this is lower than Regeneron Pharmaceuticals Inc 's recent average Revenue improvement of 31.27%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 122 other companies have achieved higher Revenue growth. While Regeneron Pharmaceuticals Inc ' s Revenue growth of 16.73% ranks overall at the positon no. 2686 in the second quarter 2026.


REGN Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 2.51 % 10.33 % 0.58 %
3rd Quarter September - 0.9 % 10.65 % 14.53 %
2nd Quarter June 16.73 % 3.62 % 12.32 % 10.53 %
1st Quarter March 19.04 % -3.7 % -0.54 % 6.64 %
FY   - 0.99 % 8.27 % -

Financial Statements
Regeneron Pharmaceuticals Inc 's second quarter 2026 Revenue $ 4,290.70 millions REGN's Income Statement
Regeneron Pharmaceuticals Inc 's second quarter 2025 Revenue $ 3,675.60 millions Quarterly REGN's Income Statement


REGN Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 3.46 % 1.84 % 2.13 %
3rd Quarter September - 2.14 % 4.89 % 6.48 %
2nd Quarter June 19.01 % 21.36 % 12.79 % -0.13 %
1st Quarter March -7.18 % -20.07 % -8.42 % -7.39 %
FY (Year on Year)   - 0.99 % 8.27 % -


Back to REGN Growth rate Comparisons >> Back to REGN Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #123
Healthcare Sector #384
Overall #2686

Revenue Y/Y Growth Statistics
High Average Low
209.2 % 31.27 % -25.07 %
(Dec 31 2012)   (Mar 31 2023)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #123
Healthcare Sector #384
Overall #2686
Revenue Y/Y Growth Statistics
High Average Low
209.2 % 31.27 % -25.07 %
(Dec 31 2012)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Regeneron Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
103.21 % 8.01 % -40.12 %
(Jun 30 2021)  


REGN's II. Quarter Q/Q Revenue Comment
Regeneron Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 19.01%, to $ 4,290.70 millions, from $3,605.40 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Regeneron Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 530.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #101
Overall #530
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #101
Overall #530
Revenue Q/Q Growth Statistics
High Average Low
103.21 % 8.01 % -40.12 %
(Jun 30 2021)  


REGN's II. Quarter Q/Q Revenue Comment
Regeneron Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 19.01%, to $ 4,290.70 millions, from $3,605.40 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Regeneron Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 530.


Regeneron Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 15,534.70 $ 14,919.60 $ 14,342.90 $ 14,247.80 $ 14,214.20
Y / Y Revenue Growth (TTM) 9.29 % 5.92 % 0.99 % 2.89 % 5.38 %
Year on Year Revenue Growth Overall Ranking # 1768 # 1654 # 160 # 1586 # 1384
Seqeuential Revenue Change (TTM) 4.12 % 4.02 % 0.67 % 0.24 % 0.91 %
Seq. Revenue Growth (TTM) Overall Ranking # 2686 # 2498 # 472 # 1912 # 1772


Cumulative Revenue growth Comment
Although Regeneron Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 31.27% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 9.29% year on year, from 5.92% in Mar 31 2026.

In the Healthcare sector 278 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1654 to 1768.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 279
Overall # 1768

Revenue TTM Y/Y Growth Statistics
High Average Low
209.2 %
 31.27 %
-25.07 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 384
S&P 500 # 2686
Cumulative Revenue growth Comment
Although Regeneron Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 31.27% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 9.29% year on year, from 5.92% in Mar 31 2026.

In the Healthcare sector 278 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1654 to 1768.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 279
Overall # 1768

Revenue TTM Y/Y Growth Statistics
High Average Low
209.2 %
31.27 %
-25.07 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 384
S&P 500 # 2686




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
REGN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Intuitive Surgical Inc 29.27%$ 29.272 millions
Xeris Biopharma Holdings Inc 28.74%$ 28.741 millions
Ultragenyx Pharmaceutical Inc 28.53%$ 28.532 millions
Innoviva Inc 28.39%$ 28.391 millions
Electrocore Inc 28.03%$ 28.031 millions
Lightwave Logic Inc 27.91%$ 27.909 millions
American Shared Hospital Services27.15%$ 27.149 millions
Protalix Biotherapeutics inc 27.07%$ 27.066 millions
Alkermes Plc 26.97%$ 26.968 millions
Lucid Diagnostics Inc 26.74%$ 26.741 millions
Lifestance Health Group Inc 26.08%$ 26.076 millions
Ani Pharmaceuticals Inc25.87%$ 25.866 millions
Sight Sciences Inc 25.83%$ 25.830 millions
Grail Inc 25.72%$ 25.723 millions
Fortress Biotech Inc 25.66%$ 25.658 millions
Apyx Medical Corp25.27%$ 25.273 millions
Radnet Inc 24.99%$ 24.986 millions
Precipio inc 24.18%$ 24.178 millions
Krystal Biotech Inc 24.14%$ 24.135 millions
Viemed Healthcare Inc 23.85%$ 23.853 millions
Ardelyx inc 23.77%$ 23.771 millions
Insulet Corporation23.51%$ 23.509 millions
Veracyte Inc 23.45%$ 23.448 millions
Journey Medical Corp23.33%$ 23.326 millions
Twist Bioscience Corporation23.24%$ 23.235 millions
Axogen inc 23.06%$ 23.065 millions
Vericel Corporation22.48%$ 22.481 millions
Milestone Scientific Inc 22.28%$ 22.276 millions
Alpha Teknova Inc 22.05%$ 22.045 millions
X4 Pharmaceuticals Inc21.64%$ 21.642 millions


About Regeneron Pharmaceuticals Inc Revenue Growth Rates (REGN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Regeneron Pharmaceuticals Inc (CIK 872589).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000872589-26-000025
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Regeneron Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.